Journal: International Journal of Molecular Sciences

Article Title: Proinflammatory Cytokine Preconditioning Enhances the Therapeutic Potency of Different Types of MSCs in Inflammation

doi: 10.3390/ijms27094090

Figure Lengend Snippet: Cytomix increased the expression of immunomodulatory markers on BM-MSCs, iMSCs WT and iMSCs B2M KO. The gating strategy is shown in . ( A ) Histogram charts of the expression of the immunomodulatory markers on BM-MSCs, iMSCs WT and iMSCs B2M KO. ( B – H ) Cytomix significantly increased the expression levels of HLA-ABC on BM-MSCs and iMSCs WT, HLA-DR on BM-MSCs, CD54 on all types of MSCs, CD200 on iMSCs WT, CD119 and CD120b on BM-MSCs, and CD274 on iMSCs WT and iMSCs B2M KO. Representative results of three independent experiments are shown. Results are shown as mean ± SD ( n = 3 in each group) and analysed by two-way ANOVA with Šídák’s multiple comparisons test or Tukey’s multiple comparisons test. */**/***/**** represent comparisons of naïve vs. Cytomix in each type of MSC; $/$$$/$$$$ represent comparisons of BM-MSCs vs. iMSCs WT vs. iMSCs B2M KO in the naïve group; ##/###/#### represent comparisons of BM-MSCs vs. iMSCs WT vs. iMSCs B2M KO in the Cytomix group with significance levels of p < 0.05/0.01/0.001/0.0001, respectively. Nd represents not detectable.

Article Snippet: The cells were centrifuged at 300× g for 5 min and resuspended in 100 μL FACS buffer containing anti-human HLA-ABC-VioGreen, HLA-DR-VioBlue, CD54-APC, CD274-PE-Vio ® 615, CD119-FITC (Cat# 130-120-436, 130-111-794, 130-121-342, 130-122-811, 130-099-931; Miltenyi Biotec, Bergisch Gladbach, Germany), CD120b-PE and CD200-PE-CY7 antibodies (Cat# 358403, 399805; BioLegend, San Diego, CA, USA).

Techniques: Expressing

Journal: Cell Research

Article Title: Genetic correction of ?-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice

doi: 10.1038/cr.2012.23

Figure Lengend Snippet: Hematopoietic differentiation of β-thalassemia-iPS cells and genetic corrected iPS cells in vivo. (A) Flow cytometry analysis of human cell (human HLA-ABC+) ratio in peripheral blood cells, BM cells from transplantation sides and untransplantation sides of the four groups of SCID mice transplanted with α-MEM, hES-HPs, piPS-HPs, and ciPS-HPs separately 6 weeks after transplantation. (B) Flow cytometry analysis of human CD71+ cells ratio in BM cells and spleen cells of the four group SCID mice transplanted with α-MEM, hES-HPs, piPS-HPs, and ciPS-HPs, separately 6 weeks after transplantation. (C) HPLC analysis of human β-globin gene expression in peripheral blood cells of the four groups of SCID mice transplanted with α-MEM (i), hES-HPs (ii), piPS-HPs (iii), and ciPS-HPs (iiii) separately 6 weeks after transplantation. (D) Western blotting of three protein absorption peaks eluted from HPLC using hemolysates from ciPS-HP group mice. Specific human β-globin antibody was used. (E) Changes in HB levels (left panel) and RBC accounts (right panel) in the peripheral blood of the four groups of SCID mice transplanted with α-MEM, hES-HPs, piPS-HPs, and ciPS-HPs separately from week 0 to week 4 after transplantation. Error bars represent S.D. (n = 5). HB, hemoglobin; RBC, red blood cell; BM, bone marrow; HP, hematopoietic progenitor cell.

Article Snippet: After washing with FACS buffer, cells were stained with anti-human HLA-ABC-FITC monoclonal antibody (BD), and incubated with Red Blood Cell Lysis Buffer (Tiagen) to remove the RBC, and then resuspended in FACS buffer and analyzed using MoFlo XDP cell sorter (Beckman Coulter Inc).

Techniques: In Vivo, Flow Cytometry, Transplantation Assay, Expressing, Western Blot